Clinical trial · Observational
A Cross-sectional Study on the Association of Peptidoglycan Fragments Derived From Gut Microbiota With Colorectal Cancer
NCT06379412CI-TRIAL-00076515unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this observational study is to explore the association of peptidoglycan fragments derived from gut microbiota with colorectal cancer (CRC). The main question it aims to answer is: Are peptidoglycan fragments from the gut microbiota associated with the progression of colorectal cancer? Participants will provide biological specimens (blood, feces, colon tissue obtained during surgery)
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| observational study, no intervention | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- label
- Colorectal Cancer(CRC)
- description
- People who are diagnosed with CRC by colonoscopy and pathological biopsy
- interventionNames
- Other: observational study, no intervention
- label
- Colorectal adenoma(CRA)
- description
- People who are diagnosed with CRA by colonoscopy and pathological biopsy
- interventionNames
- Other: observational study, no intervention
- label
- Colorectal polyp(CRP)
- description
- People who are diagnosed with CRP by colonoscopy and pathological biopsy
- interventionNames
- Other: observational study, no intervention
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * People who underwent total colonoscopy in gastroenteroscopy room. * People who agree to participate in this study and are willing to sign informed consent. Exclusion Criteria: * Previous diagnosis of malignant tumors other than colorectal cancer. * Received any of the following drug treatments within 1 month before sample collection: ① Drugs used for the treatment of colorectal diseases; ② Antibiotics; ③probiotics; ④ Laxatives. * Patients with a family history of colorectal cancer.
References
Publications (0)
Data not yet available
No reference posted for this study.